Long-term safety and effectiveness of drug-eluting stents compared to bare metal stents in ST elevation myocardial infarction: Findings from the Guthrie Health Off-label Stent (GHOST) Registry

Journal of Interventional Cardiology

Volumn 25, Issue 2, 2012, Pages 118-125

  Sattur, Sudhakar ^a   Orshaw, Pam ^a   Boura, Judy ^a   Harjai, Kishore J ^a  

^a GUTHRIE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PACLITAXEL; PROTON PUMP INHIBITOR; RAPAMYCIN; WARFARIN;

ADULT; AGED; ARTICLE; BARE METAL STENT; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DYSLIPIDEMIA; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; CORONARY ANGIOGRAPHY; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; REGISTRIES; STENTS; TREATMENT OUTCOME;

EID: 84859715215     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2011.00703.x     Document Type: Article

References (20)

1. Stone GW, Lansky AJ, Pocock SJ, et al,. HORIZONS-AMI trial investigators. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2000; 360 (19): 1946-1959.
2. Spaulding C, Henry P, Teiger E, et al,. TYPHOON investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355 (11): 1093-1104.
3. Valgimigli M, Campo G, Arcozzi C, et al,. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa inhibitor infusion in patients with myocardial infarction: Results from the STRATEGY study. J Am Coll Cardiol 2007; 50: 138-145.
4. Laarman GJ, Suttorp MJ, Dirksen MT, et al,. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355: 1105-1113.
5. Menichelli M, Parma A, Pucci E, et al,. Randomized trial of sirolimus eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 2007; 49: 1924 -1930.
6. Steg PG, Fox KA, Eagle KA, et al,. Global Registry of Acute Coronary Events (GRACE) Investigators. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 2009; 30: 321-329.
7. Vink MA, Dirksen MT, Suttorp MJ, et al,. Five year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: A follow-up study of the PASSION (paclitaxel-eluting versus conventional stent in myocardial infarction with ST-segment elevation) trial. JACC Cardiovasc Interv 2011; 4 (1): 24-29.
8. Kaltoft A, Kelbaek H, Thuesen L, et al,. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (drug elution and distal protection in acute myocardial infarction) trial. J Am Coll Cardiol 2010; 56 (8): 641-645.
9. Leibundgut G, Nietlispach F, Pittl U, et al,. Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable anginaâComparison of the effects of drug-eluting versus bare-metal stents. Am Heart J 2009; 158 (2): 271-276.
10. Di Lorenzo E, De Luca G, Sauro R, et al,. The PASEO (paclitaxel or sirolimus-eluting stent versus bare metal stent in primary angioplasty) randomized trial. JACC Cardiovasc Interv 2009; 2 (6): 515-523.
11. Hill ME, Rosenwaike I,. The Social Security Administration's Death Master File: The completeness of death reporting at older ages. Soc Secur Bull 2001; 64 (1): 45-51.
12. Cutlip DE, Windecker S, Mehran R, et al,. Academic research consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344 -2351.
13. Gualano SK, Gurm HS, Share D, et al,. Temporal trends in the use of drug-eluting stents for approved and off-label indications: A longitudinal analysis of a large multicenter percutaneous coronary intervention registry. Clin Cardiol 2010; 33 (2): 111-116.
14. Joner M, Finn AV, Farb A, et al,. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
15. Virmani R, Guagliumi G, Farb A, et al,. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus eluting stent: Should we be cautious? Circulation 2004; 109: 701-705.
16. Brodie B, Pokharel Y, Fleishman N, et al,. Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: A 15-year single-center experience. JACC Cardiovasc Interv 2011; 4 (1): 30-38.
17. Stone GW, Witzenbichler B, Guagliumi G, et al,. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): Final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377 (9784): 2193-2204.
18. Pan XH, Chen YX, Xiang MX, et al,. A meta-analysis of randomized trials on clinical outcomes of paclitaxel-eluting stents versus bare-metal stents in ST-segment elevation myocardial infarction patients. J Zhejiang Univ Sci B 2010; 11 (10): 754-761.
19. Antman EM, Anbe DT, Armstrong PW, et al,. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110 (5): 588-636.
20. Grines CL, Bonow R, Casey DE, et al,. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115 (6): 813-818.